Information for general public

Summary:

What is EBiSC?

EBiSC is a not-for-profit ‘stem cell biobank’, which stores and shares a particular type of stem cell to make them easily available to researchers in Europe and around the world. EBiSC was initially founded through collaborations supported by European funding and included universities, small research organisations and large pharmaceutical companies. It is now operated by facilities within EU and the United Kingdom.

EBiSC provides an important resource for researchers, who want to use stem cells to help understand disease, to develop new drugs and to find new methods for creating therapies that might in future replace or treat damaged and diseased tissue.

EBiSC supports lots of different research projects which are aiming to advance biomedical research. Sharing stem cells and data has the potential to generate long term public health benefits and increase social well-being. EBiSC charges a reasonable fee to researchers who obtain these stem cells from the Bank to sustain operations of the bank, allowing new stem cells to be collected and covering costs for re-stocking and performing quality checks on the cells.

iPSC lines are valuable resources that are made available for research, thanks to the willingness of research participants. Here’s an example of how a participant could engage in iPSC research:

What kind of stem cells does EBiSC work with?

EBiSC works with a type of stem cell called ‘induced pluripotent stem cells’, or iPSCs. These are a type of ‘pluripotent’ stem cell, which means that they can grow into most cell types in the human body, such as muscle, nerve, or liver cells. These cells are made from samples of tissue (donated by adults and sometimes children), such as blood, skin or hair follicles, and ‘induced’ in the laboratory to become pluripotent. They are different from embryonic stem cells, which are naturally pluripotent and can only be made from an early stage developing embryo. This kind of induced pluripotent stem cell can be cultured and expanded in a laboratory and can theoretically survive forever. The founders of the groundbreaking iPSC technology, Sir John B Gurdon and Shinya Yamanaka, were awarded the 2012 Nobel Prize in Medicine or Physiology.

These cells are very useful research tools as it means stem cells can be generated from individuals diagnosed with a disease and their disease can then be modelled in a laboratory to better understand how a disease is caused, how it progresses and to find new treatments. Importantly, they are made from tissue from individuals who have been fully informed and are willingly consenting to tissue donation.

Individuals volunteer to donate tissue (e.g. a blood sample) to researchers, who then make iPS cells from it. Without EBiSC, the iPS cells likely remain with the laboratory who originally made it. With EBiSC, we can share these cells to many research laboratories worldwide, making iPSC research easier and more accessible and helping to accelerate research.

What does EBiSC do?

EBiSC collects stem cells which have been generated by different research organisations so that we can share them with other researchers. This means we:

More information: